Search clinical trials for: Maximally tolerated dose

Total 20918 results

Cornerstone Pharmaceuticals

Completed

To Evaluate Maximally Tolerated Dose (MTD), Safety and Efficacy of CPI-613® (Devimistat) Plus Hydroxychloroquine in Patients With Relapsed or Refractory Clear Cell Sarcoma of Soft Tissue

Sarcoma, Clear Cell

United States
Albert Einstein College of Medicine
National Cancer Institute (NCI)

Withdrawn

A Dose Finding Study of CycloSam® Combined With External Beam Radiotherapy

Osteosarcoma | Bone Metastases

United States
Esperion Therapeutics, Inc.

Completed

A Study Evaluating the Safety and Efficacy of Bempedoic Acid Plus Ezetimibe Fixed-Dose Combination Compared to Bempedoic Acid, Ezetimibe, and Placebo in Patients Treated With Maximally Tolerated Statin Therapy

Hyperlipidemias

United States
National Cancer Institute (NCI)

Terminated

Depsipeptide/Flavopiridol Infusion for Cancers of the Lungs, Esophagus, Pleura, Thymus or Mediastinum

Carcinoma, Non-Small-Cell Lung | Esophageal Neoplasms | Mesothelioma | Carcinoma, Small Cell

United States
AbbVie

Completed

A Study to Evaluate the Safety and Pharmacokinetics ABBV-399 in Japanese Participants With Solid Tumors

Advanced Solid Tumors Cancer

Japan
Grünenthal GmbH

Completed

A Clinical Study in Healthy Adults Who Sometimes Take Drugs for Pleasure to Investigate the Safety and Tolerability of GRT0151Y and to Find Out Which Single Dose of the Compound is Maximally Tolerated

Pain | Chronic Pain | Acute Pain

Canada
GlaxoSmithKline

Completed

Phase I Study to Assess the Safety, Pharmacokinetics, & Pharmacodynamics of GSK923295 in Subjects w/ Refractory Cancer

Cancer

United States
LEO Pharma

Completed

Vasoconstriction Trial With LEO 90100 Aerosol Foam

Psoriasis Vulgaris

France
National Cancer Institute (NCI)

Completed

Phase I and Pharmacokinetic Trial of Phenylbutyrate Given as a Continuous Infusion in Pediatric Patients With Refractory Malignancy

Brain Neoplasms | Neuroblastoma

United States
Boehringer Ingelheim

Not yet recruiting

A Study to Test How Well Different Doses of BI 3034701 Are Tolerated by Healthy Men and People With Overweight or Obesity

Healthy
Boehringer Ingelheim

Recruiting

A Study in Healthy People to Test How Well Different Doses of BI 3000202 Are Tolerated and How They Affect the Way the Body Handles Midazolam

Healthy

Belgium
Boehringer Ingelheim

Recruiting

A Study in Healthy Japanese Men to Test How Well Different Doses of BI 3006337 Are Tolerated

Healthy

Japan
Boehringer Ingelheim

Recruiting

A Study in Healthy Men to Test How Different Doses of BI 3031185 Are Tolerated and How Food Influences the Amount of BI 3031185 in the Blood

Healthy

Germany
Boehringer Ingelheim

Recruiting

A Study to Test How Well Multiple Doses of BI 765423 Are Tolerated by Healthy Men

Healthy

Belgium
Boehringer Ingelheim

Recruiting

A Study in Healthy Men to Test How Well Different Doses of BI 1584862 Are Tolerated

Healthy

Japan
Boehringer Ingelheim

Recruiting

DAREON™-7: A Study to Test How Well Different Doses of BI 764532 in Addition to Chemotherapy Are Tolerated by People With Advanced Neuroendocrine Cancers

Neuroendocrine Neoplasms

United States, Spain, Germany, Japan
Boehringer Ingelheim

Recruiting

A Study in Healthy Men to Test How Well Different Doses of BI 3802876 Are Tolerated

Healthy

Belgium
Boehringer Ingelheim

Recruiting

DAREONᵀᴹ-8: A Study to Test How Well Different Doses of BI 764532 in Addition to Standard of Care Are Tolerated by People With Advanced Small Cell Lung Cancer (DAREONᵀᴹ-8)

Small Cell Lung Carcinoma (SCLC)

Spain, Belgium, Japan, France, Poland, Germany
Boehringer Ingelheim

Recruiting

A Study to Test How Well Different Doses of BI 3706674 Are Tolerated by People With Advanced Cancer in the Stomach and Oesophagus

Solid Tumor, KRAS Mutation

United States, Taiwan, Japan
Sichuan Enray Pharmaceutical Sciences Company

Recruiting

Carbon Nanoparticle-Loaded Iron [CNSI-Fe(II)] in the Treatment of Advanced Solid Tumor (CNSI-Fe(II))

Cervical Cancer | Breast Cancer | Colorectal Cancer | Ovarian Cancer | Lung Cancer | Advanced Solid Tumor | Pancreas Cancer | Thyroid Cancer | Vulva Cancer

China
NewAmsterdam Pharma

Recruiting

Study of Obicetrapib & Ezetimibe Fixed Dose Combination on Top of Maximum Tolerated Lipid-Modifying Therapies (TANDEM)

Dyslipidemias | Hypercholesterolemia | Familial Hypercholesterolemia | High Cholesterol | ASCVD

United States
Boehringer Ingelheim

Recruiting

DAREON™-9: A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With Small Cell Lung Cancer When Taken Together With Topotecan

Small Cell Lung Carcinoma (SCLC)

United Kingdom, Germany, France, Poland
Boehringer Ingelheim

Recruiting

A Study in Healthy People to Test How Well Repeated Doses of BI 3032950 Are Tolerated

Healthy

Belgium
Medical College of Wisconsin

Not yet recruiting

Phase I Trial of BCMA-TGF-BETA CAR-T Cells in Relapsed, Refractory Myeloma

Multiple Myeloma
Boehringer Ingelheim

Recruiting

A Study to Test How Well Different Doses of BI 3006337 Are Tolerated by People With Overweight or Obesity and With Fatty Liver Disease

Obesity | Non-alcoholic Fatty Liver Disease

United States
Boehringer Ingelheim

Recruiting

A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With a Tumour in the Brain That is Positive for DLL3

Glioma

Spain, United States, Switzerland, Germany
Grace Lim, MD, MS
National Institute of Mental Health (NIMH)

Recruiting

Ketamine Tolerated Dose for Postpartum Depression and Pain After Cesarean Delivery

Pain, Postoperative | Depression, Postpartum

United States
Boehringer Ingelheim

Recruiting

A Study to Test How Well Different Doses of BI 764532 in Combination With Ezabenlimab Are Tolerated by People With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3

Neuroendocrine Neoplasms | Small Cell Lung Carcinoma (SCLC)

Germany, Belgium, Japan, France
Boehringer Ingelheim

Recruiting

A Study to Test How Well Different Doses of BI 1815368 Are Tolerated by Healthy Men

Healthy

Belgium
Technische Universität Dresden
German Cancer Research Center

Recruiting

A Phase I Trial to Establish the Safety and Maximum Tolerated Dose of High-affinity Autologous BCMA-targeting Chimeric Antigen Receptor (CAR) T-cells in Patients With Relapsed and Refractory B-cell Malignancies (CARLOTTA01)

Neoplasms | Multiple Myeloma in Relapse | Multiple Myeloma, Refractory | Relapsed Diffuse Large B-cell Lymphoma (DLBCL) | Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Germany
Regeneron Pharmaceuticals

Recruiting

A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment (LINKER-MM4)

Multiple Myeloma

United States, France
Boehringer Ingelheim

Recruiting

A Study in Healthy Men to Test How Well Multiple Doses of BI 1839100 Are Tolerated and How BI 1839100 Influences the Amount of Other Medicines in the Blood

Healthy

Netherlands
Boehringer Ingelheim

Recruiting

A Study to Test How Well Different Doses of BI 765250 Are Tolerated by People With a Skin Disease Called Plaque Psoriasis

Psoriasis

Bulgaria, Romania, Moldova, Republic of, Georgia
Regeneron Pharmaceuticals

Recruiting

A Trial to Learn if Single Ascending Intravenous (IV) Doses of REGN7508 Are Safe and Well Tolerated, and How it Works in the Body of Healthy Adult Participants

Healthy Volunteer

United Kingdom
Beijing 302 Hospital

Not yet recruiting

Exploration of Dalpiciclib + Chidamide in HR+/HER2- Advanced Breast Cancer After Failure of CDK4/6 Inhibitor: a Phase Ⅰb Study

HR+/HER2- Advanced Breast Cancer

China
Allarity Therapeutics
Amarex Clinical Research

Recruiting

Study to Determine the Maximum Tolerated Dose (MTD) of PARPi 2X-121 Monotherapy and the MTD of Dovitinib in Combination With 2X-121 in Patients With Advanced Solid Tumors

Advanced Solid Tumors

United States
Boehringer Ingelheim

Recruiting

A Study to Test How Different Doses of BI 1703880 in Combination With Ezabenlimab Are Tolerated in People With Different Types of Advanced Cancer (Solid Tumours)

Solid Tumors

Spain, Japan, United Kingdom, United States
Boehringer Ingelheim

Recruiting

A Study to Determine How BI 907828 (Brigimadlin) is Taken up in the Tumor (Phase 0) and to Determine the Highest Dose of BI 907828 (Brigimadlin) That Could be Tolerated (Phase 1a) in Combination With Radiation Therapy in People With a Brain Tumor Called Glioblastoma

Glioblastoma

Belgium, Spain, United States
Novartis Pharmaceuticals

Recruiting

Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Cardiovascular Events (V-PLAQUE)

Coronary Artery Disease

United States, Italy, Spain, France, Korea, Republic of, Hungary, Japan, Argentina, China, India, Belgium, Switzerland, United Kingdom, Canada, Australia, Brazil, Chile, Ireland
Boehringer Ingelheim

Recruiting

A Study in People With Advanced Cancer to Test How Well Different Doses of BI 770371 Alone or in Combination With Ezabenlimab Are Tolerated

Solid Tumors

United States, Japan, Canada
Medical College of Wisconsin
Barbara Ann Karmanos Cancer Institute; Cornerstone Pharmaceuticals

Recruiting

CPI-613 (Devimistat) in Combination With Chemoradiation in Patients With Pancreatic Adenocarcinoma

Pancreas Adenocarcinoma

United States
Zhuhai Yufan Biotechnologies Co., Ltd

Recruiting

A Phase I/II Study to Evaluate the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects With Advanced Solid Tumors

Advanced Solid Tumor | Advanced Solid Malignancies

China
AIO-Studien-gGmbH
Deutsche Krebshilfe e.V., Bonn (Germany)

Recruiting

D,L-MEthadone and mFOLFOX6 in Treatment of Advanced Colorectal Cancer (MEFOX)

Chemo-refractory Colorectal Carcinoma

Germany
Boehringer Ingelheim

Recruiting

A Study in Healthy Japanese and Chinese Men to Test How Well Different Doses of BI 706321 Are Tolerated

Healthy

Japan
Zhuhai Yufan Biotechnologies Co., Ltd

Recruiting

A Phase I Study, Evaluating the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects With Advanced Solid Tumors

Advanced Solid Tumor | Advanced Solid Malignancies

United States
Nimbus Saturn, Inc.

Recruiting

A Study of NDI 1150-101 in Patients With Solid Tumors

Solid Tumor

United States
ABL Bio, Inc.

Recruiting

Study to Evaluate the Safety and Tolerability of ABL501, and to Determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of ABL501 in Subjects With Any Progressive, Locally Advanced (Unresectable) or Metastatic Solid Tumors

Advanced Solid Tumor

Korea, Republic of
Boehringer Ingelheim

Recruiting

A Study in Healthy Men to Test How Well Different Doses of BI 1569912 Are Tolerated

Healthy

Germany
Eutilex

Recruiting

A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors

Renal Cell Carcinoma | Non-Small Cell Lung Cancer | Solid Tumor | Prostate Cancer | Renal Cell Cancer Metastatic

United States, Korea, Republic of
Advenchen Laboratories Nanjing Ltd.

Recruiting

A Phase I Study of AL8326 in Advanced Solid Tumor

Advanced Solid Tumors

China

3

Subscribe